IgG3 regulates tissue-like memory B cells in HIV-infected individuals

Similar documents
Several B cell abnormalities have been described in HIV infection

HD1 (FLU) HD2 (EBV) HD2 (FLU)

Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific

Supporting Information

and follicular helper T cells is Egr2-dependent. (a) Diagrammatic representation of the

Supplemental Table 1. Clinical and epidemiological characteristics of the

Supplementary Materials for

SUPPLEMENT Supplementary Figure 1: (A) (B)

Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4

Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads

Supplemental Figure S1

Intermediate monocytes in ANCA vasculitis: increased surface. expression of ANCA autoantigens and IL-1β secretion in response. to anti-mpo antibodies

Eosinophils are required. for the maintenance of plasma cells in the bone marrow

Supplementary Figure 1.

Supplementary Figure 1. Efficiency of Mll4 deletion and its effect on T cell populations in the periphery. Nature Immunology: doi: /ni.

CD14 + S100A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer

Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood

Incomplete immune response to Coxsackie B viruses. associates with early autoimmunity against insulin

Supplementary Figure 1. Using DNA barcode-labeled MHC multimers to generate TCR fingerprints

x Lymphocyte count /µl CD8+ count/µl 800 Calculated

Treatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques

Supplementary Table 1 Clinicopathological characteristics of 35 patients with CRCs

Supplementary Figure 1: Equilibrium binding analyses of the interaction of efgartigimod with human FcRn

Supplementary Figure S1. PTPN2 levels are not altered in proliferating CD8+ T cells. Lymph node (LN) CD8+ T cells from C57BL/6 mice were stained with

Nature Immunology: doi: /ni Supplementary Figure 1. RNA-Seq analysis of CD8 + TILs and N-TILs.

Nature Immunology: doi: /ni Supplementary Figure 1. Transcriptional program of the TE and MP CD8 + T cell subsets.

Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir

Nature Immunology: doi: /ni Supplementary Figure 1. Characteristics of SEs in T reg and T conv cells.

Supplementary Figures

Nature Medicine: doi: /nm.2109

Nature Immunology doi: /ni.2771

Supplementary Figure 1. BMS enhances human T cell activation in vitro in a

Generation of ST2-GFP reporter mice and characterization of ILC1 cells following infection

Supplementary Figure 1. Double-staining immunofluorescence analysis of invasive colon and breast cancers. Specimens from invasive ductal breast

Quantification of intracellular payload release from

SUPPLEMENTARY MATERIAL

Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer

Supplementary Information

Nature Immunology: doi: /ni Supplementary Figure 1. Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice.

Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to

Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism

Social deficits in Shank3-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition

Theme 14 Ranking tests

a surface permeabilized

Nature Protocols: doi: /nprot Supplementary Figure 1

SUPPLEMENTARY MATERIAL

a b c Esophageal eosinophilia

ILC1 and ILC3 isolation and culture Following cell sorting, we confirmed that the recovered cells belonged to the ILC1, ILC2 and

Supplemental Materials

Supplementary Data. Treg phenotype

T-bet + B cells are induced by human viral infections and dominate the HIV gp140

BRIEF REPORT METHODS. Twenty-seven HIV-infected individuals receiving ART for a median of 2 years were included in this study (Table 1).

Supplementary Information

SUPPLEMENTARY INFORMATION

Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin

Nature Immunology: doi: /ni Supplementary Figure 1. DNA-methylation machinery is essential for silencing of Cd4 in cytotoxic T cells.

Evaluation of a Single-Platform Technology for Lymphocyte Immunophenotyping

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors

SUPPLEMENTARY INFORMATION

Two distinct mechanisms for experiencedependent

Supplementary Figure 1

Supplemental Information. A Visual-Cue-Dependent Memory Circuit. for Place Navigation

Supplementary Materials

Meaning-based guidance of attention in scenes as revealed by meaning maps

Nature Medicine doi: /nm.3957

Integrin v 3 targeted therapy for Kaposi s sarcoma with an in vitro evolved antibody 1

Supplementary Figure 1

(a) Significant biological processes (upper panel) and disease biomarkers (lower panel)

Supplementary Figure 1. Generation of knockin mice expressing L-selectinN138G. (a) Schematics of the Sellg allele (top), the targeting vector, the

Supplementary Figure 1. mrna targets were found in exosomes and absent in free-floating supernatant. Serum exosomes and exosome-free supernatant were

LPS CD40 + IL-4. Vorinostat (24 Hours) Vorinostat (24 Hours) Panobinostat (24 Hours) Panobinostat (24 Hours) Romidepsin (48 Hours)

Supplementary Materials for

PD-1 and its ligand PD-L1 are progressively up-regulated on CD4 and CD8 T-cells. in HIV-2 infection irrespective of the presence of viremia

CD25-PE (BD Biosciences) and labeled with anti-pe-microbeads (Miltenyi Biotec) for depletion of CD25 +

COPD lungs show an attached stratified mucus layer that separate. bacteria from the epithelial cells resembling the protective colonic

activation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows

Figure S1. Gating strategy used in NK cells and γδ T lymphocytes coculture An example of flow cytometry analysis shows the gating of NK cells and γδ

Supplemental Materials for. Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to. FTY720 during neuroinflammation

Supplementary Figure 1 Protease allergens induce IgE and IgG1 production. (a-c)

ONLINE SUPPLEMENTAL INFORMATION

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-

Supplementary Figure 1 Information on transgenic mouse models and their recording and optogenetic equipment. (a) 108 (b-c) (d) (e) (f) (g)

Human and mouse T cell regulation mediated by soluble CD52 interaction with Siglec-10. Esther Bandala-Sanchez, Yuxia Zhang, Simone Reinwald,

Supplementary Data Table of Contents:

SUPPLEMENTARY INFORMATION

Supplemental Information. Aryl Hydrocarbon Receptor Controls. Monocyte Differentiation. into Dendritic Cells versus Macrophages

Nature Neuroscience: doi: /nn Supplementary Figure 1. Trial structure for go/no-go behavior

Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel

Supplementary Figure 1. Immune profiles of untreated and PD-1 blockade resistant EGFR and Kras mouse lung tumors (a) Total lung weight of untreated

Supplementary Information:

Journal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

Suppl Video: Tumor cells (green) and monocytes (white) are seeded on a confluent endothelial

Supplementary Information. A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of

Nature Structural and Molecular Biology: doi: /nsmb Supplementary Figure 1

Supplementary Figure 1 Lymphocytes can be tracked for at least 4 weeks after

Supplementary. presence of the. (c) mrna expression. Error. in naive or

Supplementary material. VAMP7 controls T cell activation by regulating recruitment and phosphorylation of vesicular

Fluorochrome Panel 1 Panel 2 Panel 3 Panel 4 Panel 5 CTLA-4 CTLA-4 CD15 CD3 FITC. Bio) PD-1 (MIH4, BD) ICOS (C398.4A, Biolegend) PD-L1 (MIH1, BD)

Transcription:

SUPPLEMENTARY INFORMATION Articles https://doi.org/10.1038/s41590-018-0180-5 In the format provided by the authors and unedited. IgG3 regulates tissue-like memory B cells in HIV-infected individuals Lela Kardava 1,6, Haewon Sohn 2,6, Christine Youn 1, James W. Austin 1, Wei Wang 1, Clarisa M. Buckner 1, J. Shawn Justement 1, Valerie A. Melson 1, Gwynne E. Roth 2, Marissa A. Hand 1, Kathleen R. Gittens 3, Richard W. Kwan 3, Michael C. Sneller 1, Yuxing Li 4,5, Tae-Wook Chun 1, Peter D. Sun 2, Susan K. Pierce 2 and Susan Moir 1 * 1 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 2 Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 3 Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA. 4 Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA. 5 Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA. 6 These authors contributed equally to this work: Lela Kardava, Haewon Sohn. *e-mail: smoir@niaid.nih.gov Nature Immunology www.nature.com/natureimmunology

Supplementary Figure 1 Additional cell-surface analyses. (a) Flow cytometry of CD20-gated B cells isolated from the peripheral blood of HIV-negative, HIV-aviremic and chronically infected HIV-viremic individuals, and stained for IgG1 and total IgG (tigg) with pan anti-igg mab. (b) Flow cytometry of CD20-gated B cells isolated from the peripheral blood of a chronically infected HIV-viremic individual, and stained for IgG3 and tigg with pan anti-igg mab clones G18-145, M1310G05 and ICO-97. (c) Gating strategy to evaluate mean fluorescence intensities (MFI) of B cell-bound IgG3. Staining for IgG3 and tigg (clone G18-145) was used to identify cell-bound IgG3 by excluding tigg/igg3 double positive CD20gated B cells with a clear diagonal pattern. IgG3 MFI was then determined for all B cells, as well as tissue-like memory (TLM) and naïve (N) B cells defined by expression of CD27 and CD21, as indicated in the representative plot and histograms. Data are representative of 10 (HIV-negative), 14 (HIV-aviremic) and 49 (HIV-viremic) individual experiments (a) or one experiment representative of eight independent experiments (b) or one representative of 106 individual experiments (c).

Supplementary Figure 2 Factors that influence IgG3 IgM B cells. (a) Longitudinal flow cytometry for IgG3 and IgM of CD20-gated B cells isolated from an HIV-infected individual during early viremia and one year later in chronic stage of viremia. Similarly, B cells from a chronically infected HIV-viremic individual were stained for IgG3 and IgM before and 10 years after sustained suppression of viremia by ART. (b) Comparison by stage of HIV infection and status of viremia of frequencies of IgG3 IgM and TLM B cells measured by flow cytometry, as well as of HIV viral load and CD4 T- cell counts. Dotted line represents limit of detection. (c) Comparison by stage of HIV infection and status of viremia of mean fluorescence intensities (MFI) for IgG3 measured by flow cytometry of CD20-gated TLM and naïve B cells where IgG3-expressing B cells were excluded, as described in Methods and Supplementary Fig. 1c. (d) Comparison of IgG3 MFI on TLM versus naïve B cells of 92 HIV-viremic individuals, all stages of disease combined. Red horizontal bars represent medians; each symbol (b,c) represents an individual in early viremia (n = 16), chronic viremia (n = 73) or aviremia (n = 17); * P < 0.05, ** P < 0.01, *** P 0.001 and **** P < 0.0001; n.s., not significant (two-tailed Mann-Whitney test after obtaining significance by Kruskal-Wallis ANOVA test on full set (b,c) or two-tailed Wilcoxon matched-pairs signed rank test (d)). Data are representative of five (early to chronic viremic) and seven (chronic viremic to aviremic) individual experiments (a).

Supplementary Figure 3 PEG-IgG3 isolated from serum of HIV-viremic individuals with high-intensity IgG3 on IgM B cells bind to B cells of HIVnegative individuals. (a) Flow cytometry of CD20-gated B cells of an HIV-negative individual incubated without (no treatment) or with PEG-IgG3 isolated from sera of HIV-viremic individuals with low- or high-intensity IgG3 on IgM B cells. Bottom: cumulative data from paired sera of HIV-viremic individuals with high (yellow; n = 12) or low (light green; n = 12) intensity IgG3 on IgM B cells. Heat map depicts % of IgM-expressing B cells from HIV-negative individuals with bound IgG3 following incubation with serum-derived PEG precipitate or bead-enriched IgG3. PEG-IgG3 isolated with serum from individuals with high-intensity IgG3 on IgM B cells bound B cells of HIV negative individuals with a median 39%, compared to 0% from those with low-intensity IgG3 on IgM B cells (P = 0.005). For bead enriched IgG3, the medians were 8.2% for high versus 1.8% for low-intensity IgG3 on IgM B cells (P = 0.009). P values, two-tailed Wilcoxon matched-pairs signed rank test. (b) Flow cytometry of CD20-gated B cells of an HIV-negative individual incubated without (no treatment) or with PEG-IgG3 isolated from the serum of HIV-viremic individuals with low- or high-intensity IgG3 on IgM B cells. The plots show IgG3 and IgM staining for TLM and naïve B cells, defined by the expression of CD21 and CD27. (c) Comparison of / calcium uptake by HIV-negative IgD (D) TLM and naïve (N) B-cell IgG3 (G3) populations treated with PEG-IgG3 isolated from serum of chronically infected HIV-viremic individuals with moderate to high-intensity IgG3 on IgM B cells. Each color coded symbol represents an individual (n = 6); black horizontal bars represent medians; * P < 0.05; n.s., not significant (two-tailed Wilcoxon matched-pairs signed rank test after obtaining significance by Friedman ANOVA test on full set). Data are representative of 12 individual experiments (b).

Supplementary Figure 4 IgG3 serum levels and binding to HIV-negative B cells. (a) Comparison of levels and ratios of IgG subclasses in serum of HIV-viremic individuals with high (n = 12) or low (n = 12) intensity IgG3 on IgM B cells (same serum used in Supplementary Fig. 3). Red horizontal bars represent medians; *** P < 0.001 and **** P < 0.0001; n.s., not significant (two-tailed Mann-Whitney test). (b) Flow plots of CD20-gated B cells of an HIV-negative individual incubated without (no treatment) or with heat-aggregated IgG3 fractionated into SEC-1 or SEC-2. (c) Representative flow plots of CD20-gated B cells of an HIV-negative individual incubated without (no treatment) or with PEG precipitate or with SEC-1 or SEC-2 fractions isolated from PEG-precipitated serum of an HIV-viremic individual with high-intensity IgG3 on IgM B cells. Right, cumulative data from sera of HIV-viremic individuals with moderate- to high-intensity IgG3 on IgM B cells. Each color coded symbol represents an individual (n = 6); black horizontal bars represent medians; * P < 0.05 (two-tailed Wilcoxon matched-pairs signed rank test after obtaining significance by Friedman ANOVA test on full set). Data are representative of three (b) or six (c) independent experiments.

Supplementary Figure 5 Role of CD32b, C1q, CRP and glycosylation in non-aggregated IgG3 binding to B cells of HIV-negative individuals. (a) Immunoblot analysis of C1q, IgG3 and CRP content in PEG precipitate (PEG), SEC-1, SEC-2 or SEC-2 depleted of C1q (C1q-d SEC-2) using serum of an HIV-viremic individual with moderate-intensity IgG3 on IgM B cells. The gels are shown in the order the membrane was sequentially stained and stripped. Lanes marked IgG3 and C1q indicate respective protein controls. (b) Flow cytometry of CD20-gated B cells of an HIV-negative individual incubated without PEG-IgG3 (no treatment), with PEG-IgG3 from serum of an HIV-viremic individual with moderate-intensity IgG3 on IgM B cells treated with control rabbit IgG or rabbit anti-c1q or rabbit anti-crp antibody. Right, cumulative pattern from sera of chronically infected HIV-viremic individuals with moderate- to high intensity IgG3 on IgM B cells. (c) Flow cytometry of CD20-gated B cells of an HIV-negative individual stained for IgG3 and IgM. The B cells were untreated or treated with antibody to CD32b or control goat IgG prior to addition of PEG-IgG3 from an HIV-viremic individual with high-intensity IgG3 on IgM B cells. Graph: cumulative effect of pre-treating B cells with anti-cd32b prior to addition of PEG-IgG3 from HIV-viremic individuals with moderate- to high-intensity IgG3 on IgM B cells (n = 6). (d) Effect of treating PEGIgG3 prepared from individuals with moderate- to high-intensity IgG3 on IgM B cells with PNGase F or EndoS2 on binding to B cells of HIV-negative individuals. Each color coded symbol (b,d) represents an individual (b, n = 7; d, n = 6); black horizontal bars represent medians; * P < 0.05; n.s., not significant (two-tailed Wilcoxon matched-pairs signed rank test, after (b,d) obtaining significance by Friedman ANOVA test on full set). Data are representative of eight independent experiments (a).

2024 © healthdocbox.com Privacy Policy | Terms of Service | Feedback